Antibody drug conjugates (ADCs) are a rapidly evolving therapeutic class that exploits the target-selectivity of monoclonal antibodies (MAbs) to deliver drugs to antigen-expressing cells. The regulatory approval of ADCs in both hematologic malignancies (brentuximab vedotin) and solid tumors (ado-trastuzumab emtansine) clearly demonstrates the clinical potential of ADCs. In general, ADCs consist of a targeting MAb covalently attached to a drug payload via a cleavable or non-cleavable linker. Although simple in concept, to achieve the design goal of improved therapeutic efficacy and improved safety, each of the components of an ADC; the MAb, linker and drug need to considered in the context of the targeted antigen, the selectivity of antigen expression and the biology of the tumor type on which the target antigen is expressed. There is now clinical information, of various levels of maturity, available on over 40 ADCs. This meeting will discuss the current state of ADC design and modifications that may improve both the efficacy and safety of this treatment modality.

Antibody drug conjugates: Design considerations for improving efficacy and safety

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.